Racial Disparity Seen in Mortality for Peds End-Stage Renal Disease

This article originally appeared here.
Share this content:
Racial Disparity Seen in Mortality for Peds End-Stage Renal Disease
Racial Disparity Seen in Mortality for Peds End-Stage Renal Disease

FRIDAY, Dec. 30, 2016 (HealthDay News) -- For children with end-stage renal disease starting renal replacement therapy (RRT) there is racial disparity in the risk of death, according to a study published online Dec. 29 in the Journal of the American Society of Nephrology.

Elaine Ku, M.D., from the University of California, San Francisco, and colleagues compared the mortality risk among a cohort of non-Hispanic black, Hispanic, and non-Hispanic white children (12,123 children) who started RRT from 1995 to 2011. The children were followed through 2012. About 25 and 26 percent of the children were non-Hispanic black and of Hispanic ethnicity, respectively.

The researchers found that during a median follow-up of 7.1 years, 1,600 children died. The risk of death was 36 percent higher for non-Hispanic black children (95 percent confidence interval, 1.21 to 1.52) and 34 percent lower for Hispanic children (95 percent confidence interval, 0.57 to 0.77), compared with non-Hispanic white children. The higher risk of death in non-Hispanic black children was attenuated after adjustment for transplant as a time-dependent covariate (hazard ratio, 0.99; 95 percent confidence interval, 0.88 to 1.12); the lower risk persisted in Hispanic children (hazard ratio, 0.59; 95 percent confidence interval, 0.51 to 0.68).

"Parity in access to transplantation in children, and improvements in strategies to prolong graft survival, could substantially reduce disparities in mortality risk of non-Hispanic black children treated with RRT," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »